Glucagon-like peptide-1 (GLP-1) has a central role in type 2 diabetes (T2D) due to its potentiating effects on insulin secretion and the successful use of GLP-1 analogs in T2D therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.